Tag: core

Experts Reveal 2025 Dog Gut Health Findings, Ingredient Transparency Push, and the Rise of Targeted Canine Probiotics

Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In Tempus (TEM) To Contact Him Directly To Discuss Their Options

LUXEMBOURG , Aug. 02, 2025 (GLOBE NEWSWIRE) -- Bitcoin Swift, a blockchain protocol combining Proof-of-Work (PoW), Proof-of-Stake (PoS), and an AI-powered Proof-of-Yield (PoY) mechanism, has officially entered Stage 3 of its presale. The platform is offering tokens at $3 during this limited 64-day window, with a scheduled increase to $4 in the next stage and a confirmed launch price of $15.

TORONTO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Lumine Group Inc. (“Lumine Group” or “the Company”) (TSXV:LMN) announces financial results for the three and six months ended June 30, 2025. All amounts referred to in this press release are in US dollars unless otherwise stated.

CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten public offering of 43,700,000 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 5,700,000 additional shares of its common stock, at a public offering price of $3.30 per share. The underwriters did not receive any discounts or commissions with respect to an aggregate of 1,818,181 shares of common stock sold to the Cystic Fibrosis Foundation. All of the shares of common stock in the offering were sold by Prime Medicine. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $144.2 million.

SAN FRANCISCO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Before the markets opened on July 25, 2025, investors in Centene Corporation (NYSE: CNC) saw the price of their shares decline about 10% in pre-market trading after the company reported disastrous Q2 2025 financial results.